Research articleLong term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study
References (42)
Human T-cell leukaemia virus type I and neurological disease
Curr. Opin. Neurobiol.
(1993)- et al.
Clinical and virological effects of high-dose recombinant interferon-α in disseminated AIDS-related Kaposi's sarcoma
Lancet
(1988) - et al.
Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis
Lancet
(1985) - et al.
Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy
J. Neurol. Sci.
(1994) - et al.
Anti-viral and immunomodulatory effects of interferon-α on cultured lymphocytes from patients with human T lymphotropic virus type I-associated myelopathy (HAM/TSP)
J. Neuroimmunol.
(1995) Immune response to retroviruses in the central nervous system
- et al.
Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy
J. Neurol. Sci.
(1991) - et al.
Antibody titers to HTLV-I-P40tax protein and gag-env hybrid protein in HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with increased HTLV-I proviral DNA load
J. Neurol. Sci.
(1992) - et al.
In vivo infection of human T-cell leukemia virus type I in non-T cells
Virology
(1993) - et al.
The effect of intraventricular interferon on subacute sclerosing panencephalitis
Brain Dev.
(1989)
Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy
Lancet
Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis
Virology
Interferon-alpha treatment in HTLV-I-associated myelopathy: studies of clinical and immunological aspects
J. Neurol. Sci.
Soluble CD4 and CDS in the peripheral blood of patients with multiple sclerosis and HTLV-I-associated myelopathy
J. Neuroimmunol.
Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial
N. Engl. J. Med.
Long term recombinant interferon alpha treatment in MS with special emphasis to side effects
Multiple Sclerosis
Recombinant leukocyte interferon treatment of chronic hepatitis B
Hepatology
High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease
J. Exp. Med.
Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C
Clin. Exp. Immunol.
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine
N. Engl. J. Med.
Serum levels of soluble interleukin-2 receptors and effects of interferon-α for patients with chronic hepatitis C virus
Dig. Dis. Sci.
Cited by (45)
An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers
2021, Pharmacology and TherapeuticsCitation Excerpt :INF-α is the only drug that was tested for the treatment of HAM/TSP in a randomized controlled trial, which demonstrated that a 4-week IFN-α therapy improved neurological symptoms (Izumo et al., 1996). However, according to the national registry of patients with HAM/TSP in Japan, INF-α is currently used by only a small proportion of patients, presumably because of the lack of evidence of its long-term benefit and various adverse effects (Arimura et al., 2007; Coler-Reilly et al., 2016; Tsutsumi et al., 2019; Yamasaki et al., 1997). Corticosteroid therapy is currently the most widely accepted treatment for HAM/TSP, although no randomized, controlled trial was performed (Bangham et al., 2015; Coler-Reilly et al., 2016).
Infectious Myelopathies
2018, Neurologic ClinicsCitation Excerpt :Motor disability has been shown to improve, but this is usually not sustained. Other agents, such as interferon-alfa,79 cyclosporine A,80 methotrexate,81 and pentoxifylline,82 have been used with variable success. Prosultiamine83 and pentosan polysulfate sodium84 have shown some promise in small open trials.
Neurologic disease due to HTLV-1 infection
2014, Handbook of Clinical NeurologyCitation Excerpt :Treatment caused a significant reduction in PBL count and a non-significant trend to reduction in serum immunoglobulin and CSF IgG (Kuroda et al., 1992). In another open trial, 6.0 MU natural human IFN-α was administered to 7 Japanese HAM patients for 22 weeks and resulted in sustained improvement in 5 (70%) (Yamasaki et al., 1997). An uncontrolled follow-up surveillance study found 66.2% of 152 patients were mildly or markedly improved at 4 weeks and 36.7% of 30 patients were improved 5 or more months after therapy was stopped (Arimura et al., 2007).
The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran
2012, Journal of NeuroimmunologyCitation Excerpt :They found that 6 out of their 7 patients responded to this treatment. Moreover, the number of peripheral blood lymphocyte with HTLV-1 genome significantly decreased during the treatment (Yamasaki et al., 1997). Later, in 1999, the safety and efficacy of the long-term administration of subcutaneous recombinant IFN-α was reported in a 37‐year old Brazilian patient with HAM/TSP with a sustained improvement in the motor performance after a 2 year follow up (Gazzola et al., 1999).
Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy
2008, Neurologic ClinicsCitation Excerpt :The benefit of long-term interferon-α therapy, however, has not been well studied. A small study extending interferon-α treatment to 24 weeks reported sustained clinical response [86]. The main marker of efficacy during interferon-α therapy appears to be a reduction in HTLV-I proviral load [60].